51Âþ»­

Shropshire-based Genvolt is demonstrating how bioproduct design technologies can unlock new markets as they begin a new Knowledge Transfer Partnership (KTP) with 51Âþ»­ Leicester (51Âþ»­).

The partnership research will use high voltage power supplies, biomedical engineering, and healthcare sciences to develop advances in emerging technologies. Genvolt's recent success has already created new job opportunities in the region, with the company planning to employ more members of staff in the future to meet demand.



The new partnership with 51Âþ»­ combines academics with experienced electrical engineers, supports the company's ambitious growth plans by opening further opportunities to expand into different national and international markets.

Stuart Morgan, Managing Director of Genvolt, said: "It is our responsibility to keep pushing the boundaries of technologies to provide world-first innovative solutions that will enable different industry sectors to change our world."

Incorporating financial support from Innovate UK, KTPs aim to help businesses innovate. They connect businesses to partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth.

The partnership's goal is to strategically bridge the gap between existing expertise in electrical device engineering via bespoke integration of current products into emerging platform technologies for the pharmaceutical industry. These processes have the potential to rival existing technologies and methods by operating at ambient temperature, pressure, and environments.

The KTPs combination of high voltage power supplies, technology advancement and scientific research will help Genvolt maintain its status as a market leader by delivering technologically advanced and pioneering products to the progressive pharmaceutical sectors.

Mr Morgan added: "There is now, more than ever, a critical requirement to identify and develop modern technologies that provide innovative, forward-thinking methods of drug delivery systems.

“Genvolt's knowledge of advanced technology and skills, alongside a collaboration with the highly regarded 51Âþ»­, will help us achieve these goals. We aim to deliver scalable solutions that address the challenges faced, and we are looking to have our first product to market as early as March 2022."

Dr Rhianna Briars, Knowledge Exchange officer at 51Âþ»­, said: “I’m really looking forward to seeing this project progress. It is a great example of how a business with the ambition to do something new and widen their market opportunities can work with academics, in turn benefitting the research community."

51Âþ»­’s knowledge exchange team recruited experienced scientific researcher Kazem Nazari to collaborate with the team at Genvolt in researching and developing new drug delivery methods. Kazem has a PhD in Pharmaceutical Engineering, Pharmaceutics and Drug Design with experience in formulation and chemical analytical techniques.

Kazem has previously worked on projects employing EHDA technology for pharmaceutical and biomaterial ambits. He said: “I’m delighted to be a part of the KTP venture between 51Âþ»­ and Genvolt. “I am looking forward to working alongside the staff at Genvolt, and also having access to the expertise and advice of their design and engineering team on some exciting ground-breaking projects."